← Back to headlines
EU Approves New Migraine Drug, Offering Breakthrough for Millions
The European Commission has approved Aquipta (atogepant) for the acute treatment of migraine attacks in adults, marking a significant development that could benefit millions, particularly in countries like Poland.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
DRC Launches Ebola Vaccination Campaign as UN Seeks $1.1 Billion in Funding
3h ago
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
6h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
8h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
13h ago